Recent advances in the design of RAR a and RAR ß agonists as orally bioavailable drugs. A review (2020)
Attributed to:
A phase 1 trial of a retinoic acid receptor beta agonist for the treatment of spinal cord injury
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.bmc.2020.115664
PubMed Identifier: 33069074
Publication URI: http://europepmc.org/abstract/MED/33069074
Type: Journal Article/Review
Parent Publication: Bioorganic & Medicinal Chemistry
Issue: 20
ISSN: 0968-0896